Literature DB >> 12077102

Underdiagnosis of hereditary haemochromatosis: lack of presentation or penetration?

E Ryan1, V Byrnes, B Coughlan, A-M Flanagan, S Barrett, J C O'Keane, J Crowe.   

Abstract

BACKGROUND: The majority of hereditary haemochromatosis (HH) patients are homozygous for the C282Y mutation in the HFE gene. We have demonstrated a homozygote frequency of 1 in 83 for the C282Y mutation in a retrospective analysis of Irish neonates. However, a fully developed phenotype is not observed at the same frequency clinically, suggesting that a large proportion of Irish HH patients may remain undiagnosed. AIMS: To determine whether underdiagnosis of HH results from the non-specific nature of early symptoms or incomplete penetrance of the C282Y mutation.
METHODS: Seventy nine C282Y homozygous individuals identified from family screening for HH and 30 HH probands were investigated. Non-specific symptoms (fatigue, arthropathy, and impotence) and their association with iron indices (transferrin saturation and serum ferritin) and hepatic iron deposition were analysed.
RESULTS: We found that 78% of men (mean age 42 years) and 36% of women (mean age 39 years) who were identified as C282Y homozygotes following family screening had iron overload, as defined by a transferrin saturation >or=52% combined with a serum ferritin >or=300 microg/l for men and >or=200 microg/l for women. The frequency of reports of non-specific symptoms in those individuals with iron overload was not significantly different from those who did not have iron overload.
CONCLUSIONS: Our findings indicate that underdiagnosis of HH may be due to the non-specific nature of early symptoms and less frequently to the incomplete penetrance of the C282Y mutation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12077102      PMCID: PMC1773286          DOI: 10.1136/gut.51.1.108

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  Clinical features of genetic hemochromatosis in women compared with men.

Authors:  R Moirand; P C Adams; V Bicheler; P Brissot; Y Deugnier
Journal:  Ann Intern Med       Date:  1997-07-15       Impact factor: 25.391

Review 2.  Diagnosis of hemochromatosis.

Authors:  L W Powell; D K George; S M McDonnell; K V Kowdley
Journal:  Ann Intern Med       Date:  1998-12-01       Impact factor: 25.391

3.  H63D is an haemochromatosis associated allele.

Authors:  V F Fairbanks; D J Brandhagen; S N Thibodeau; K Snow; P C Wollan
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

4.  A simple genetic test identifies 90% of UK patients with haemochromatosis. The UK Haemochromatosis Consortium.

Authors: 
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

5.  HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis.

Authors:  C Mura; O Raguenes; C Férec
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

6.  A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote.

Authors:  D F Wallace; J S Dooley; A P Walker
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

7.  Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis.

Authors:  C E McLaren; G J McLachlan; J W Halliday; S I Webb; B A Leggett; E C Jazwinska; D H Crawford; V R Gordeuk; G D McLaren; L W Powell
Journal:  Gastroenterology       Date:  1998-03       Impact factor: 22.682

8.  The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis.

Authors:  P C Adams; Y Deugnier; R Moirand; P Brissot
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

Review 9.  Hemochromatosis: genetics helps to define a multifactorial disease.

Authors:  W Burke; N Press; S M McDonnell
Journal:  Clin Genet       Date:  1998-07       Impact factor: 4.438

10.  Hemochromatosis in Ireland and HFE.

Authors:  E Ryan; C O'keane; J Crowe
Journal:  Blood Cells Mol Dis       Date:  1998-12       Impact factor: 3.039

View more
  7 in total

Review 1.  Liver inflammation and fibrosis.

Authors:  Yukinori Koyama; David A Brenner
Journal:  J Clin Invest       Date:  2017-01-03       Impact factor: 14.808

2.  Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients.

Authors:  C A McCune; D Ravine; K Carter; H A Jackson; D Hutton; J Hedderich; M Krawczak; M Worwood
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

3.  The celtic coincidence--the frequency and clinical characterisation of hereditary haemochromatosis in patients with coeliac disease.

Authors:  J Leyden; B Kelleher; E Ryan; S Barrett; J C O'Keane; J Crowe
Journal:  Ir J Med Sci       Date:  2006 Jan-Mar       Impact factor: 1.568

Review 4.  Screening for hemochromatosis: patients with liver disease, families, and populations.

Authors:  Sumedha P Galhenage; Charlie H Viiala; John K Olynyk
Journal:  Curr Gastroenterol Rep       Date:  2004-02

5.  A study of 82 extended HLA haplotypes in HFE-C282Y homozygous hemochromatosis subjects: relationship to the genetic control of CD8+ T-lymphocyte numbers and severity of iron overload.

Authors:  Eugénia Cruz; Jorge Vieira; Susana Almeida; Rosa Lacerda; Andrea Gartner; Carla S Cardoso; Helena Alves; Graça Porto
Journal:  BMC Med Genet       Date:  2006-03-01       Impact factor: 2.103

6.  Quality of life utility values for hereditary haemochromatosis in Australia.

Authors:  Barbara de Graaff; Amanda Neil; Kristy Sanderson; Kwang Chien Yee; Andrew J Palmer
Journal:  Health Qual Life Outcomes       Date:  2016-02-29       Impact factor: 3.186

7.  A new 500 kb haplotype associated with high CD8+ T-lymphocyte numbers predicts a less severe expression of hereditary hemochromatosis.

Authors:  Eugénia Cruz; Chris Whittington; Samuel H Krikler; Cláudia Mascarenhas; Rosa Lacerda; Jorge Vieira; Graça Porto
Journal:  BMC Med Genet       Date:  2008-11-06       Impact factor: 2.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.